Valuation: Evotec SE

Market Cap 606M 697M 564M 518M 978M 66.56B 993M 6.65B 2.61B 33.14B 2.62B 2.56B 111B P/E 2026 *
-3.96x
P/E 2027 * -9.88x
Enterprise Value 648M 745M 603M 553M 1.05B 71.12B 1.06B 7.11B 2.79B 35.41B 2.8B 2.74B 119B EV / Sales 2026 *
1.08x
EV / Sales 2027 * 0.97x
Free-Float
89.91%
Yield 2026 *
-
Yield 2027 * -
1 day-1.10%
1 week-0.12%
1 month-31.92%
3 months-33.76%
6 months-44.01%
Current year-37.22%
1 week 3.43
Extreme 3.428
3.52
1 month 3.24
Extreme 3.238
5.19
Current year 3.24
Extreme 3.238
6.66
1 year 3.24
Extreme 3.238
7.49
3 years 3.24
Extreme 3.238
23.48
5 years 3.24
Extreme 3.238
45.7
10 years 3.24
Extreme 3.238
45.7
Manager TitleAgeSince
Chief Executive Officer 55 01/07/2024
Director of Finance/CFO - 01/05/2026
Chief Operating Officer - 01/05/2026
Director TitleAgeSince
Director/Board Member 58 19/06/2019
Director/Board Member 64 01/06/2021
Director/Board Member 43 22/06/2022
Change 5-day change 1-year change 3-year change Capi.($)
-1.10%-0.12% - - 697M
-1.40%+2.59%-1.71%+11.28% 48.53B
-2.41%-0.90%+403.17%+614.40% 39.87B
-1.16%+12.96%+26.45%+5.03% 38.68B
-1.88%-3.03%+4.94%+47.52% 35.13B
-1.74%+5.12%+9.58%+46.02% 29.79B
-2.85%-3.92% - - 16.08B
-0.21%-4.04%+35.09%+127.95% 16.11B
-0.64%+2.65%+1.25%+8.92% 13.61B
-1.19%-1.32%-3.32%-34.94% 12.62B
Average -1.46%+1.05%+59.43%+103.27% 27.82B
Weighted average by Cap. -1.59%+2.03%+76.87%+128.10%

Financials

2026 *2027 *
Net sales 600M 690M 558M 512M 968M 65.85B 983M 6.58B 2.58B 32.78B 2.59B 2.53B 110B 736M 847M 685M 629M 1.19B 80.84B 1.21B 8.08B 3.17B 40.24B 3.18B 3.11B 135B
Net income -147M -169M -137M -126M -237M -16.16B -241M -1.61B -634M -8.05B -636M -622M -26.98B -47.45M -54.59M -44.17M -40.55M -76.58M -5.21B -77.77M -521M -204M -2.59B -205M -201M -8.7B
Net Debt 41.5M 47.74M 38.63M 35.46M 66.97M 4.56B 68.01M 455M 179M 2.27B 179M 175M 7.61B 105M 121M 97.89M 89.87M 170M 11.55B 172M 1.15B 453M 5.75B 454M 444M 19.28B
Logo Evotec SE
Evotec SE is a Germany-based drug discovery and development company. The company is engaged in development of new pharmaceutical products through research alliances and development partnerships with pharmaceutical and biotechnology companies, academic institutions, patient organizations and venture capital companies. The drug discovery solutions are provided in the form of fee-for-service work, integrated drug discovery alliances, development partnerships, licensing of drug candidates and consulting arrangements. Evotec SE operates in a number of areas, including neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases and fibrosis. Its pipeline covers a range of therapeutic areas, such as CNS Insomnia, Chronic cough, immunology & inflammation, women’s health endometriosis, nephrology, dermatological diseases, fibrotic disease and antiviral, among others.
Employees
4,526
Date Price Change Volume
31/07/26 EUR 3.428 -1.10% 2,200
30/07/26 EUR 3.466 +0.52% 2,400
29/07/26 EUR 3.448 -1.15% 8,040
28/07/26 EUR 3.488 -.--% 1,400
27/07/26 EUR 3.488 +1.63% 11,225
Trader
Investor
Global
Quality
ESG MSCI
AAA
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
8
Last Close Price
3.410EUR
Average target price
4.900EUR
Spread / Average Target
+43.70%

Quarterly revenue - Rate of surprise